About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, July 6th, 2017

The QualityStocks
Daily Stock List


Silver Bull Resources, Inc. (SVBL)

TopPennyStockMovers, Wall Street Resources, RedChip, Streetwise Reports, StreetInsider, Stockhouse, and Stock Stars reported earlier on Silver Bull Resources, Inc. (SVBL), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Silver Bull Resources, Inc. is a mineral exploration company listed on the OTCQB. Its flagship project is named "Sierra Mojada". This Project is situated 150 kilometers north of the city of Torreon in Coahuila, Mexico. The Project is highly prospective for silver and zinc. An exploration stage enterprise, Silver Bull Resources has its corporate office in Vancouver, British Columbia.

The Company’s Sierra Mojada Project is 100 percent owned and operated by Silver Bull Resources. It is part of a large land package consisting of 40 mining concessions totaling 21,167 hectares (52,305 acres), located in an historical high-grade silver, lead, zinc mining district discovered in 1879.

Sierra Mojada has premier infrastructure. This infrastructure includes a railway to the site; a paved road; grid power, as well as five company-owned water wells. The Sierra Mojada Project has an NI (National Instrument) 43-101 compliant measured and indicated Global resource of 58.7 million tonnes grading at 3.6 percent zinc and 50 g/t silver for 4.670 billion pounds of zinc and 90.8 million ounces of silver.

The main mineralization zone found at Sierra Mojada extends more than six kilometers in an East-West direction along the base of the Sierra Mojada Range parallel with the Sierra Mojada fault. More than 54 historical mine shafts lie along this strike, mining to depths in excess of 200 meters. This region has not been mined with modern mining technology and processes. Sierra Mojada is an open pittable oxide deposit.  

Silver Bull Resources announced in June of 2015 that it identified more high-grade massive sulphide mineralization at its Sierra Mojada Project. The new sulphide mineralization lies within a 1.4-kilometer-long east-west trending chargeability anomaly. The Company identified new massive sulphide mineralization grading 690 g/t silver, 1 percent copper, 4.8 percent lead, and 15.25 percent zinc at Sierra Mojada.

Silver Bull Resources announced in September of 2016 that it began an exploration program to target potential sulphide mineralization at depth believed to be underneath and adjacent to, the main zone of mineralization already defined at Sierra Mojada. During August and September of 2016, it completed a 590-line kilometer airborne magnetic geophysics survey over the main deposit at Sierra Mojada targeting structures at depth.

In addition, greater than 20,000 meters of drill core was re-logged over areas of high interest and a new structural model was developed for the main deposit. On November 14, 2016, the Company announced that it began an initial 3,000-meter exploration drill program using Major Drilling at the Sierra Mojada project in Coahuila.

In March of this year, Silver Bull Resources announced the results of its recent exploration drill program targeting deep structures on the Sierra Mojada Project. The above-mentioned work identified several deep structures coincident with known high grade historical silver and zinc mines in the region and were the primary targets for the drill program.

Silver Bull Resources, Inc. (SVBL), closed Thursday's trading session at $0.0759, up 1.20%, on 27,600 volume with 9 trades. The average volume for the last 60 days is 194,330 and the stock's 52-week low/high is $0.0605/$0.21.

Cell MedX Corp. (CMXC)

The Observer, StockBlogs, SECFilings News, PennyStockLocks, ResearchOTC, FatCat Stocks, StockRockandRoll, Daily Stock Motion, Penny Pick Insider, SMS Penny Picks, Penny Stocks VIP, Wall Street Beauties, and WINNINGOTC reported earlier on Cell MedX Corp. (CMXC), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Cell MedX Corp centers on the discovery, development, and commercialization of therapeutic and non-therapeutic products, which promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, and high blood pressure. This is through developing technologies to help manage illness and related complications. It is at the frontline of creating devices that treat chronic and acute conditions for clinical and self-management care. Listed on the OTCQB, Cell MedX is based in Carson City, Nevada.

An early development stage bio-technology enterprise, the Company manufactures and distributes medical devices powered by its proprietary, patented technology of low level current principally for supporting chemical (pharmaceutical) treatments for diabetes. Cell MedX is making safe, results-oriented technologies combining electro-chemical applications and establishing new levels of treatment, named cellular medicine. In addition, through its wholly-owned subsidiary, Avyonce Cosmedics, Inc., the Company involves in the reselling and marketing of technology and equipment to the global wellness industry and providing continuing education to health care professionals.  

Cell MedX’s aim is to release its initial lineup of commercial products. It will commence with its flagship product named ‘eBalance’, which works to improve the efficacy of the client’s existing medication regimes. The eBalance brand includes consumer product development and professional versions for use within medical facilities. The design of them are to address accelerated wound healing, abatement of diabetic neuropathies, improvement with glucose control, insulin resistance, as well as blood pressure.

The eBalance technology will form the basis for a product line, which will be available to assist in the management of diabetes mellitus (T1DM and T2DM) and its complications, as a professional clinic-based and a home use device. The eBalance Pro wellness device is an all-in-one, portable, and fully automated microcurrent delivery system.

The Company announced this past March that it received an approval from the Ethics Review Board to begin its observational clinical trial in Canada. Cell MedX engaged Nutrasource Diagnostics, Inc. (NDI) to launch the observational clinical trial of its unique and proprietary technology branded under the trade name eBalance.

The goal of the Trial is to measure the impact of eBalance therapy as an adjunct treatment on HbA1c after three months of therapy in relation to the subject's baseline data and medical history.
Cell MedX also announced in March that it completed its registration process with the U.S. Food and Drug Administration (FDA) and initiated an application process to receive FDA clearance for use of its eBalance device as a Class II non-exempt device. Cell MedX also announced that its continuing clinical observational trial was advancing as expected.

In April, Cell MedX announced that its Canadian subsidiary entered into a production agreement with an ISO 9001 certified manufacturing facility in Coquitlam, British Columbia, and selected North American suppliers for sourcing essential components for its eBalance Pro device. The intention of the move is to enable it to facilitate its planned distribution under the present registration with the FDA while ensuring lower production costs and more control of the manufacturing and distribution process. In addition, it will assist Cell MedX with setting up its standard operating procedures under ISO 13485-2016, a requirement by Health Canada to register the Company's eBalance Pro device as Class II medical device.  

Cell MedX Corp. (CMXC), closed Thursday's trading session at $0.32405, up 1.11%, on 3,600 volume with 3 trades. The average volume for the last 60 days is 25,203 and the stock's 52-week low/high is $0.12/$0.475.

Rhino Resource Partners LP (RHNO)

TopPennyStockMovers, Wall Street Mover, Marketbeat, and PCG Advisory reported previously on Rhino Resource Partners LP (RHNO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Rhino Resource Partners LP is a diversified energy limited partnership headquartered in Lexington, Kentucky. It concentrates on coal and energy related assets and activities. This includes energy infrastructure investments. The Company is a diversified energy MLP (Master Limited Partnership) that produces coal in many basins in the United States.  Rhino Resource Partners’ shares trade on the OTC Markets’ OTCQB.

Rhino’s business strategy is to acquire coal reserves and properties with relatively long lives and that could undergo development with low risk at a reasonable cost. The Company produces metallurgical and steam coal in a variety of basins across the U.S. Also, Rhino leases coal via its Elk Horn subsidiary.

Rhino Resource Partners has completed a number of coal asset acquisitions since April of 2003 with a total purchase price of around $357.5 million. Through these acquisitions and other coal lease transactions, it has considerably increased its proven and probable coal reserves and non-reserve coal deposits. Furthermore, it has successfully grown its coal production by way of internal development projects.

The Company produces steam coal used to produce electricity and metallurgical coal utilized in the steel-making process. Additionally, the Company manages and leases coal properties and collects royalties from such management and leasing activities. Rhino also has oil and gas investments in the Cana Woodford region, which provides added cash flows to its business.

In December of 2016, Rhino Resource Partners announced that it entered into an option agreement with Royal Energy Resources, Inc. (ROYE), Rhino Resource Partners Holdings, LLC (Rhino Holdings), an entity wholly-owned by certain investment partnerships managed by Yorktown Partners LLC, and Rhino GP LLC, the general partner of Rhino. Rhino received an option (Call Option) from Rhino Holdings to acquire substantially all of the outstanding common stock of Armstrong Energy, Inc. currently owned by investment partnerships managed by Yorktown.

The Option Agreement specifies that Rhino can exercise the Call Option no earlier than January 1, 2018, and no later than December 31, 2019. In exchange for Rhino Holdings granting Rhino the Call Option to purchase Armstrong Energy, the Partnership issued 5.0 million new common units (Call Option Premium Units) to Rhino Holdings upon the execution of the Option Agreement.

Recently, Rhino Resource Partners announced its financial and operating results for the quarter ended March 31, 2017. For the quarter, the Partnership reported a Net Loss of $2.0 million and Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) of $4.8 million, versus a Net Loss of $1.2 million and Adjusted EBITDA of $6.6 million in Q1 of 2016. Diluted Net Loss Per Common Unit was $0.22 for the quarter versus Diluted Net Loss Per Common Unit of $0.33 for Q1 of 2016.

Total Revenues for the quarter were $53.6 million, with Coal Sales generating $51.8 million of the total, versus Total Revenues of $39.3 million and Coal Revenues of $36.7 million in Q1 of 2016.

Rhino Resource Partners LP (RHNO), closed Thursday's trading session at $3.25, even for the day. The average volume for the last 60 days is 1,917 and the stock's 52-week low/high is $1.75/$5.99.

CURE Pharmaceutical Holding Corp. (CURR)

MarketWatch reported on CURE Pharmaceutical Holding Corp. (CURR), and today we are highlight the Company, here at the QualityStocks Daily Newsletter.

CURE Pharmaceutical Holding Corp. is a developer and manufacturer of advanced oral thin film (CureFilm™) for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter (OTC) applications. CureFilm™ drug delivery is a next generation market alternative to traditional tablets, capsules, and liquids when delivering prescription, and OTC medications.  The Company is a fully integrated, progressive drug delivery enterprise. CURE has an industry leading full service cGMP manufacturing facility. OTCQB-listed, CURE Pharmaceutical Holding is based in Oxnard, California.

The Company provides the most advanced development and manufacturing of CureFilm™ pharmaceutical and veterinarian products in a patented and proprietary delivery system. Additionally, CURE has an array of products in cutting-edge delivery platforms. This includes sublingual and transdermal applications.

CURE Pharmaceutical takes products through the clinical process to commercialization. It serves the pharmaceutical and biotech; veterinarian; nutraceutical and medical food; and cannabinoid drug molecules market vertical sectors.

The design of CureFilm™ is for oral administration utilizing the sublingual or buccal area of the mouth. CureFilm™ has undergone development to improve upon pharma kinetic profile and the overall therapeutic index of API (Active Pharmaceutical Ingredient).

CURE is investing heavily in the development of new drug delivery technology advancements. Advances it has made include enhanced encapsulation and nano-encapsulation technologies, composition formulations, stability systems, taste masking systems, production methodologies, and primary packaging advancements.

The Company can manufacture and distribute technically complex formulations, packaging, and product lines of medicines that meet exacting standards for quality and effectiveness. CURE’s process development and manufacturing expertise is enabling it to deliver manifold delivery platforms of increasing complexity.

CURE’s technology enables differentiation within large therapeutic categories. It potentially improves patient compliance by way of its patented application of creating multiple layers, and sub-encapsulation of the delivered compound, potentially improving onset of action, lessening dosing, and enhancing efficacy, thus broadening the therapeutic index.

At the end of May, CURE Pharmaceutical announced that the CURE and the CannaKids partnership entered into a strategic research collaboration with Technion Research and Development Foundation Ltd., the wholly-owned subsidiary of the Technion-Israel Institute of Technology, to research how diverse cannabinoid compounds within cannabis strains can be used to treat various subtypes of cancer. CannaKids is a California Cooperative Corporation based in Sherman Oaks, California. It has developed a complete line of cannabinoid therapies to help aid patients with various conditions.

Yesterday, CURE Pharmaceutical announced that it expects growing demand for its novel transdermal drug delivery platform, which uses an epidermis penetration enhancer for increased functionality of its delivery matrix. A recent research report by Research and Markets predicts the Global Transdermal Drug Delivery Market to increase at a CAGR (Compound Annual Growth Rate) of roughly 11.6 percent over the next decade to reach about $95.57 billion by 2025. 

CURE Pharmaceutical Holding Corp. (CURR), closed Thursday's trading session at $7.25, down 5.84%, on 1,520 volume with 3 trades. The average volume for the last 60 days is 5,378 and the stock's 52-week low/high is $2.0499/$15.00.

BioVie, Inc. (BIVI)

Wealth Insider Alert reported previously on BioVie, Inc. (BIVI), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

BioVie, Inc. centers on the discovery, development, and commercialization of inventive drug therapies for liver disease. Presently, the clinical-stage company, is focusing on commercializing BIV201, which is a novel approach to the treatment of ascites due to chronic liver cirrhosis. BioVie is headquartered in Beverly, Massachusetts. The Company lists on the OTC Markets Group’s OTCQB.

BioVie submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) for BIV201 late in 2016. It said it was waiting on clearance to begin a clinical trial program. It said that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism.

BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a major unmet medical need. The FDA has never approved any drug specifically for treating ascites. In addition to patient suffering, U.S. treatment costs for liver cirrhosis, including ascites and other complications, are estimated at greater than $4 billion annually.

In February of this year, BioVie announced that it submitted a complete response to the FDA addressing the issues identified in the Investigational New Drug Application (IND) clinical hold letter received by the Company in January of this year.

On April 3, 2017, BioVie announced that it received notice from the FDA that the planned Phase 2a clinical trial of its new drug candidate BIV201 may begin. This was based on BioVie’s IND to conduct a study in patients with refractory or intractable ascites because of advanced liver cirrhosis.

Furthermore, the Company was notified by the US Patent and Trademark Office (USPTO) that its application for a core patent covering the use of BIV201 to decrease ascites formation in ambulatory patients was allowed.

Also, in April, BioVie announced the signing of a Cooperative Research and Development Agreement (CRADA) to conduct a Phase 2a clinical trial of BIV201 in patients with refractory or intractable ascites because of advanced liver cirrhosis. The study is titled “Safety and pharmacodynamic activity of low-dose terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites requiring recurrent large volume paracentesis."

BIV201 is a continuous infusion of the peptide terlipressin, initially undergoing development for the treatment of refractory ascites. Terlipressin, dosed differently, is approved in approximately 40 countries for other complications of liver cirrhosis coming up from an alike disease pathway. Terlipressin is not available in the United States. Recently, BioVie announced that the USPTO issued US Patent No. 9,655,945 covering the Company's new drug candidate BIV201. US Patent No. 9,655,945 may be viewed on the USPTO website.

BioVie, Inc. (BIVI), closed Thursday's trading session at $0.29, up 20.83%, on 2,000 volume with 2 trades. The average volume for the last 60 days is 6,201 and the stock's 52-week low/high is $0.12/$0.45.


The QualityStocks
Company Corner


Converde Energy USA, Inc. (XFUL)

The QualityStocks Daily Newsletter would like to spotlight Converde Energy USA, Inc. (XFUL). Today, Converde Energy USA, Inc. closed trading at $0.0043, up 26.47%, on 89,722 volume with 8 trades. The stock’s average daily volume over the past 60 days is 1,584,043, and its 52-week low/high is $0.0002/$0.10.

Converde Energy USA, Inc. (XFUL), d/b/a American Energy Partners Inc., and its group of companies are dedicated to delivering solutions wherever energy production and water meet technology. The company has positioned itself to benefit from above-favorable margins on each of its subsidiaries due to the synergy of the chain of revenues.

Hydration Company of PA (HCPA)
Hydration Company of PA focuses on sourcing, implementing and distributing reclaimed water at a profit. This subsidiary's competitive advantage mainly lies within its pure volume of reclaimed water and its access to low cost treatment with high flow rates and highly concentrated solids through the technologies of XFUL's partners. Because of the volume as well as the flexibility of the model established via patent pending methodology and conveyance methods, HCPA can effectively gain market share immediately as large corporations prefer access to one source that can supply massive amounts of reclaimed water regardless of drought conditions.

American Energy Solutions, LLC
American Energy Solutions, LLC utilizes a network of partners to provide off-the-shelf and custom-designed treatment technologies that contribute to HCPA's business model of low-cost treatment and distribution. As a provider of design, this subsidiary is capable of repeatable and synergistic services across the value chain. American Energy's long-term plan is to utilize an in-house team to grow market share as water use continues to become more critical to modern industry.

Gilbert Oil & Gas Company
Gilbert Oil & Gas Company is leveraging broad industry valuation experience to move forward on its mission to add shareholder value through drilling, operating, and partnership opportunities in the upstream oil and gas space. Equipped with the in-house capabilities necessary to source and evaluate opportunities for profitability, Gilbert is positioned to become a strong customer of XFUL's other subsidiaries, providing them with the foundation to attract other customers and enter new markets.

Integrated Business Strategy
By combining ownership of water sources via Hydration Company of PA, design and treatment solutions via American Energy Solutions, and a stream of promising opportunities via Gilbert Oil & Gas Company, XFUL is essentially creating a positive revenue feedback loop. This synergistic business model also opens opportunity for higher profit margins, additional revenue, and faster growth in new markets. Disclaimer

Converde Energy USA, Inc. Company Blog

Converde Energy USA, Inc. News:

Converde Energy USA, Inc. Appoints Josh Hickman, President of Subsidiary's O&G Operations and to Board of Directors

American Energy Partners, Inc. (XFUL) d/b/a Converde Energy USA, Inc. Engages NetworkNewsWire for Corporate Communications Solutions

Converde Energy USA, Inc. to Receive up to $3M Investment from GPL Ventures, LLC

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.1022, up 5.36%, on 6,610 volume with 6 trades. The stock’s average daily volume over the past 60 days is 96,494, and its 52-week low/high is $0.0797/$0.59.

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

Sully Project - E3 Target Drilling Underway

Kootenay Zinc Corp.: Sully Project Exploration Update

NetworkNewsWire Releases Exclusive Audio Interview with Kootenay Zinc Corp. (KTNNF)

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $0.92, up 1.10%, on 28,948 volume with 30 trades. The stock’s average daily volume over the past 60 days is 53,374 and its 52-week low/high is $0.12/$2.75.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

CFN Media Interviews ChineseInvestors.com CEO Warren Wang

ChineseInvestors.com, Inc.'s Wholly-owned Foreign Enterprise, CBD Biotechnology Co. Ltd., Will Launch its First Hemp Infused Skin Care Line in China

ChineseInvestors.com, Inc. Launches CBD Biotechnology Inc. in British Columbia, Canada

Patriot One Technologies, Inc. (PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $0.5658, off by 2.98%, on 116,031 volume with 25 trades. The stock’s average daily volume over the past 60 days is 71,560, and its 52-week low/high is $0.4665/$1.49.

Patriot One Technologies, Inc. (PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

Patriot One Initiates Pacific Rim Sales with Aotea Security of New Zealand

Patriot One Marks 3-Months of Global PATSCAN Sales with $2.7M in Signed Agreements

Patriot One Appoints Former Senior Counter Terrorism Official John Gillies to Board

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.45, even for the day, on 20,675 volume with 10 trades. The stock’s average daily volume over the past 60 days is 62,269 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Continues Market Expansion with New Customer-Requested Specialty Modules

ORHub (ORHB) Sets Exercise Price for its Series B and D Warrants

ORHub, Inc. Expands its Addressable Market with Launch of Transformative Hip and Knee Module


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(CERC) +125.40%


MarketClub Analysis
(VSTM) +41.98%


(HSNI) +26.84%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251